Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852073 | 0.88 | KCNH2 (0.53) | EPHX1DPP7POLBGABRA5GABRB2 | |
| SCHEMBL3640222 | 0.86 | KCNH2 (0.52) | EPHX1DPP7POLBGABRA5GABRB2 | |
| SCHEMBL22687353 | 0.84 | ITGB3 (0.41) | DPP7POLBDPP4FAPDPP8 | |
| SCHEMBL75440 | 0.84 | — | — | |
| Bicarbonate SCHEMBL10725172 | 0.81 | ITGB3 (0.41) | DPP7POLBDPP4FAPDPP8 | |
| Hydrochloric Acid SCHEMBL7602448 | 0.81 | — | — | |
| SCHEMBL28956884 | 0.81 | — | — | |
| Methane SCHEMBL27880200 | 0.81 | — | — | |
| SCHEMBL21911154 | 0.81 | EPHX1 (0.48) | EPHX1DPP7POLBGABRA5GABRB2 | |
| SCHEMBL12226497 | 0.81 | EPHX1 (0.48) | EPHX1DPP7POLBGABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. | 2024-10-31 | — | — | US | claimed |
| EP-4396196-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | Aimmax Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| WO-2023034481-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| CN-106470973-A | Small molecule lfa-1 inhibitors | 阿罗赛特制药公司 | 2017-03-01 | — | — | CN | claimed |
| US-20140112976-A1 | Cyclic Peptides with an Anti-Neoplasic and Anti-Angiogenic Activity | CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIA (CU) | 2014-04-24 | — | — | US | claimed |
| EP-2690107-A2 | CYCLIC PEPTIDES WITH AN ANTI-NEOPLASIC AND ANTI-ANGIOGENIC ACTIVITY | Centro De Ingenieria Genetica Y Biotecnologia (CU) | 2014-01-29 | — | — | EP | claimed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | claimed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | claimed |
| US-6670477-B2 | Reacting 4-pyridinone with glycine | NOVARTIS AG (CH) | 2003-12-30 | — | — | US | claimed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | claimed |
| US-20020133014-A1 | Synthesis of enantiomerically enriched 4-piperidinylglycine | NOVARTIS AG (CH) | 2002-09-19 | — | — | US | claimed |
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240327461-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4396196-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | Aimmax Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000075186-A1 | NEUROMEDIN B AND SOMATOSTATIN RECEPTOR AGONISTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES SAS (FR) | 2000-12-14 | — | — | WO | disclosed |
| EP-0846125-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| WO-1996040743-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133014-A1 | Synthesis of enantiomerically enriched 4-piperidinylglycine | EPRS1, GRHPR, ASNS | EPHX1 1342/4885DPP7 151/4885POLB 1920/4885 |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | EPHX1 205/4885DPP7 349/4885POLB 4086/4885 |
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | VIP, FPR2, FPR1 | EPHX1 3349/4885DPP7 187/4885POLB 969/4885 |
| US-20240327461-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | EPHX1 4133/4885DPP7 104/4885POLB 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.